Navigation Links
CryoCor Files Response to Patent Infringement Lawsuit
Date:12/6/2007

SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today that it has filed a response to the recent patent infringement lawsuit brought against it by CryoCath Technologies Inc., and confirmed that it does not believe that it infringes any valid and enforceable claim. The Company's answer to the suit was filed with the United States District Court for the District of Delaware.

Ed Brennan, Ph.D., President and Chief Executive Officer of CryoCor, said, "We are very confident in the strength of our intellectual property portfolio and continue to believe that this lawsuit is without merit. We have very carefully evaluated the claims in CryoCath's complaint and remain confident that we do not infringe any valid and enforceable claims. We will examine our options to leverage CryoCor's intellectual property position and what is in the best interests of our shareholders."

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor has completed enrollment in a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved in the United States for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com

Forward Looking Statements

The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements related to the Company's intellectual property portfolio, the merits and likely outcome of the CryoCath lawsuit, and actions CryoCor may take to leverage its intellectual property position. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors and the risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission, including risks and uncertainties relating to its intellectual property. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward-looking statements.

Contact:

CryoCor, Inc. The Ruth Group

Gregory J. Tibbitts Nick Laudico / Zack Kubow (investors)

Chief Financial Officer (646) 536-7030 / 7020

(858) 909-2200 nlaudico@theruthgroup.com

gtibbitts@cryocor.com zkubow@theruthgroup.com

Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE CryoCor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
2. CryoCor to Present at Maxim Group First Annual Growth Conference in New York
3. CryoCor Appoints New Vice President of Sales and Marketing
4. CryoCor Announces Web cast and Conference Call of Third Quarter 2007 Results
5. Alvarado Hospital Files Countersuit Against Blue Shield
6. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
7. Pharsight Files Application for Nasdaq Capital Market Listing
8. Gentiva(R) Health Services Files Universal Shelf Registration Statement
9. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
10. CIGNA Behavioral Health Offers Members Online Provider Profiles
11. American Media Operations, Inc. Files Form 10-Q For First Quarter 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
(Date:10/12/2017)... Miramar, FL (PRWEB) , ... October 12, 2017 ... ... is presenting the latest in wound care advancements to physician colleagues, skilled nursing ... lecture is titled, "Navigating the Treacherous Waters of Wound Care." , "At many ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: